Affichage 11 à 20 des 107 essais cliniques
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |
ESSAIS CLINIQUES
    No essai
    ClinicalTrials.gov ID
Phase Coordonnateur(rice)
(EN) Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ Defined by a Molecular Expression Assay Combined With Clinico-Pathological Features
    ELISA
    NCT04797299
     Actif en recrutement
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
Marianna Perna
514-934-1934 poste 43191
Concordance entre la biopsie liquide et la biopsie tissulaire dans les cas de cancer du sein métastatique nouvellement diagnostiqué
    Concordance
    NCT04241237
     Actif en recrutement
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
Neera Sriskandarajah
514-934-1934 poste 36686
(EN) The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
    CompassHER2 RD (MAC27)
    NCT04457596
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
Judith-Élise Marcoux
418-525-4444 poste 84577
(EN) RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
    BREVITY
    NCT03524430
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
Fanie Bourgault
418-525-4444 poste 82697
(EN) A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
    WO44263
    NCT05894239
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
Fanie Bourgault
418-525-4444 poste 82697
(EN) A Randomized Trial of Five-Fraction Partial Breast Irradiation
    RAPID2
    NCT05417516
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
Josée Allard
418-525-4444 poste 67296
(EN) A Prospective Multi-center Clinical Study Evaluating the Use of PD G 506 A and the Eagle V1.2 Imaging System for the Visualization of Carcinoma During Breast Conserving Surgery
    SBI-CIP 20-002
    NCT04815083
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
Marie-Caude Lépine
418-525-4444 poste 82100
(EN) A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
    TROPION-Breast05
    NCT06103864
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
Marie-Caude Lépine
418-525-4444 poste 82100
(EN) A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
    CAMBRIA-2
    NCT05952557
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
Marie-Caude Lépine
418-525-4444 poste 82100
Essai randomisé portant sur la radiothérapie régionale pour le traitement du cancer du sein avec envahissement ganglionnaire à faible risque avec biomarqueur.
    MA.39
    NCT03488693
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
Phase III Josée Allard
418-525-4444 poste 16730
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |